{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:43:20Z","timestamp":1785300200914,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"DOI":"10.7759\/cureus.91235","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T14:43:39Z","timestamp":1756478619000},"source":"Crossref","is-referenced-by-count":1,"title":["A Systematic Review of the Use of Janus Kinase Inhibitors in Large Vessel Vasculitis"],"prefix":"10.7759","author":[{"given":"Timmie","family":"Chay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tirath","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabina","family":"Dumaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srivarshini","family":"Maddukuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan  R","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga Spandana","family":"Battula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00327-5","article-title":"Large-vessel vasculitis","volume":"7","author":"Pugh D","year":"2022","unstructured":"Pugh D, Karabayas M, Basu N, et al.. Large-vessel vasculitis. Nat Rev Dis Primers. 2022, 7:93. 10.1038\/s41572-021-00327-5","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000561","article-title":"Management of large-vessel vasculitis","volume":"31","author":"Salvarani C","year":"2019","unstructured":"Salvarani C, Hatemi G. Management of large-vessel vasculitis. Curr Opin Rheumatol. 2019, 31:25-31. 10.1097\/BOR.0000000000000561","journal-title":"Curr Opin Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223480","article-title":"2022 American College of Rheumatology\/EULAR classification criteria for giant cell arteritis","volume":"81","author":"Ponte C","year":"2022","unstructured":"Ponte C, Grayson PC, Robson JC, et al.. 2022 American College of Rheumatology\/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis. 2022, 81:1647-53. 10.1136\/ard-2022-223480","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223482","article-title":"2022 American College of Rheumatology\/EULAR classification criteria for Takayasu arteritis","volume":"81","author":"Grayson PC","year":"2022","unstructured":"Grayson PC, Ponte C, Suppiah R, et al.. 2022 American College of Rheumatology\/EULAR classification criteria for Takayasu arteritis. Ann Rheum Dis. 2022, 81:1654-60. 10.1136\/ard-2022-223482","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2022.123670","article-title":"Cardiovascular lesions in giant cell arteritis","volume":"60","author":"Dzhus M","year":"2022","unstructured":"Dzhus M, Mostbauer H. Cardiovascular lesions in giant cell arteritis. Reumatologia. 2022, 60:399-407. 10.5114\/reum.2022.123670","journal-title":"Reumatologia"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13233575","article-title":"Myocardial and vascular involvement in patients with Takayasu arteritis: a cardiovascular MRI study","volume":"13","author":"Almasi S","year":"2023","unstructured":"Almasi S, Asadian S, Hosseini L, et al.. Myocardial and vascular involvement in patients with Takayasu arteritis: a cardiovascular MRI study. Diagnostics (Basel). 2023, 13:3575. 10.3390\/diagnostics13233575","journal-title":"Diagnostics (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/art.41774","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis","volume":"73","author":"Maz M","year":"2021","unstructured":"Maz M, Chung SA, Abril A, et al.. 2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 2021, 73:1349-65. 10.1002\/art.41774","journal-title":"Arthritis Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01922-1","article-title":"French recommendations for the management of Takayasu's arteritis","volume":"16","author":"Saadoun D","year":"2021","unstructured":"Saadoun D, Bura-Riviere A, Comarmond C, Lambert M, Redheuil A, Mirault T. French recommendations for the management of Takayasu's arteritis. Orphanet J Rare Dis. 2021, 16:311. 10.1186\/s13023-021-01922-1","journal-title":"Orphanet J Rare Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.019","article-title":"Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: a systematic review and meta-analysis","volume":"17","author":"Barra L","year":"2018","unstructured":"Barra L, Yang G, Pagnoux C. Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: a systematic review and meta-analysis. Autoimmun Rev. 2018, 17:683-93. 10.1016\/j.autrev.2018.01.019","journal-title":"Autoimmun Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103580","article-title":"Relapses in giant cell arteritis: updated review for clinical practice","volume":"23","author":"Alba MA","year":"2024","unstructured":"Alba MA, Kermani TA, Unizony S, Murgia G, Prieto-Gonz\u00e1lez S, Salvarani C, Matteson EL. Relapses in giant cell arteritis: updated review for clinical practice. Autoimmun Rev. 2024, 23:103580. 10.1016\/j.autrev.2024.103580","journal-title":"Autoimmun Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221961","article-title":"Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study","volume":"81","author":"Koster MJ","year":"2022","unstructured":"Koster MJ, Crowson CS, Giblon RE, et al.. Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. Ann Rheum Dis. 2022, 81:861-7. 10.1136\/annrheumdis-2021-221961","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-020-00948-x","article-title":"Pathogenesis of giant cell arteritis and Takayasu arteritis - similarities and differences","volume":"22","author":"Watanabe R","year":"2020","unstructured":"Watanabe R, Berry GJ, Goronzy JJ, Weyand CM. Pathogenesis of giant cell arteritis and Takayasu arteritis - similarities and differences. Curr Rheumatol Rep. 2020, 22:68. 10.1007\/s11926-020-00948-x","journal-title":"Curr Rheumatol Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.881705","article-title":"Perspectives of JAK inhibitors for large vessel vasculitis","volume":"13","author":"Watanabe R","year":"2022","unstructured":"Watanabe R, Hashimoto M. Perspectives of JAK inhibitors for large vessel vasculitis. Front Immunol. 2022, 13:881705. 10.3389\/fimmu.2022.881705","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1408-8","article-title":"A novel susceptibility locus in the IL12B region is associated with the pathophysiology of Takayasu arteritis through IL-12p40 and IL-12p70 production","volume":"19","author":"Nakajima T","year":"2017","unstructured":"Nakajima T, Yoshifuji H, Shimizu M, et al.. A novel susceptibility locus in the IL12B region is associated with the pathophysiology of Takayasu arteritis through IL-12p40 and IL-12p70 production. Arthritis Res Ther. 2017, 19:197.","journal-title":"Arthritis Res Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102796","article-title":"Interferon signature in giant cell arteritis aortitis","volume":"127","author":"Vieira M","year":"2022","unstructured":"Vieira M, R\u00e9gnier P, Maciejewski-Duval A, et al.. Interferon signature in giant cell arteritis aortitis. J Autoimmun. 2022, 127:102796. 10.1016\/j.jaut.2022.102796","journal-title":"J Autoimmun"},{"key":"ref16","article-title":"Targeting JAK\/STAT pathway in Takayasu's arteritis","volume":"79","author":"R\u00e9gnier P","year":"2020","unstructured":"R\u00e9gnier P, Le Joncour A, Maciejewski-Duval A, et al.. Targeting JAK\/STAT pathway in Takayasu's arteritis. Ann Rheum Dis. 2020, 79:951-9.","journal-title":"Ann Rheum Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu X","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021, 6:402. 10.1038\/s41392-021-00791-1","journal-title":"Signal Transduct Target Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220873","article-title":"Blocking GM-CSF receptor \u03b1 with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis","volume":"81","author":"Corbera-Bellalta M","year":"2022","unstructured":"Corbera-Bellalta M, Alba-Rovira R, Muralidharan S, et al.. Blocking GM-CSF receptor \u03b1 with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis. Ann Rheum Dis. 2022, 81:524-36. 10.1136\/annrheumdis-2021-220873","journal-title":"Ann Rheum Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.08.001","article-title":"Pathogenesis of Takayasu's arteritis: a 2011 update","volume":"11","author":"Arnaud L","year":"2011","unstructured":"Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z. Pathogenesis of Takayasu's arteritis: a 2011 update. Autoimmun Rev. 2011, 11:61-7. 10.1016\/j.autrev.2011.08.001","journal-title":"Autoimmun Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030423","article-title":"Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis","volume":"137","author":"Zhang H","year":"2018","unstructured":"Zhang H, Watanabe R, Berry GJ, Tian L, Goronzy JJ, Weyand CM. Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis. Circulation. 2018, 137:1934-48. 10.1161\/CIRCULATIONAHA.117.030423","journal-title":"Circulation"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky AM","year":"2022","unstructured":"Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics. 2022, 14:1001. 10.3390\/pharmaceutics14051001","journal-title":"Pharmaceutics"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05973-4","article-title":"A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis","volume":"41","author":"Rathore U","year":"2022","unstructured":"Rathore U, Thakare DR, Patro P, Agarwal V, Sharma A, Misra DP. A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis. Clin Rheumatol. 2022, 41:33-44. 10.1007\/s10067-021-05973-4","journal-title":"Clin Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S369963","article-title":"Biomarker changes and molecular signatures associated with Takayasu arteritis following treatment with glucocorticoids and tofacitinib","volume":"15","author":"Dai X","year":"2022","unstructured":"Dai X, Wang J, Zhang X, et al.. Biomarker changes and molecular signatures associated with Takayasu arteritis following treatment with glucocorticoids and tofacitinib. J Inflamm Res. 2022, 15:4395-407. 10.2147\/JIR.S369963","journal-title":"J Inflamm Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220832","article-title":"Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study","volume":"81","author":"Kong X","year":"2022","unstructured":"Kong X, Sun Y, Dai X, et al.. Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study. Ann Rheum Dis. 2022, 81:117-23. 10.1136\/annrheumdis-2021-220832","journal-title":"Ann Rheum Dis"},{"key":"ref25","article-title":"Successful use of tofacitinib in refractory Takayasu arteritis: a case series","volume":"34","author":"Mv P","year":"2023","unstructured":"Mv P, Maikap D, Padhan P. Successful use of tofacitinib in refractory Takayasu arteritis: a case series. Mediterr J Rheumatol. 2023, 34:356-62.","journal-title":"Mediterr J Rheumatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152018","article-title":"Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: a prospective study","volume":"55","author":"Wang J","year":"2022","unstructured":"Wang J, Dai X, Ma L, et al.. Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: a prospective study. Semin Arthritis Rheum. 2022, 55:152018. 10.1016\/j.semarthrit.2022.152018","journal-title":"Semin Arthritis Rheum"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003985","article-title":"Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre","volume":"10","author":"Zhou Z","year":"2024","unstructured":"Zhou Z, Fang C, Wang L, et al.. Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre. RMD Open. 2024, 10:0. 10.1136\/rmdopen-2023-003985","journal-title":"RMD Open"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa281","article-title":"Tofacitinib in patients with refractory Takayasu's arteritis","volume":"59","author":"Li J","year":"2020","unstructured":"Li J, Li M, Tian X, Zeng X. Tofacitinib in patients with refractory Takayasu's arteritis. Rheumatology (Oxford). 2020, 59:e95-8. 10.1093\/rheumatology\/keaa281","journal-title":"Rheumatology (Oxford)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1187584","article-title":"Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden","volume":"14","author":"Eriksson P","year":"2023","unstructured":"Eriksson P, Skoglund O, Hemgren C, Sj\u00f6wall C. Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden. Front Immunol. 2023, 14:1187584. 10.3389\/fimmu.2023.1187584","journal-title":"Front Immunol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03314-9","article-title":"Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature","volume":"26","author":"Loricera J","year":"2024","unstructured":"Loricera J, Tofade T, Prieto-Pe\u00f1a D, et al.. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature. Arthritis Res Ther. 2024, 26:116. 10.1186\/s13075-024-03314-9","journal-title":"Arthritis Res Ther"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.11855\/j.issn.0577-7402.2022.01.0058","article-title":"[Successful remission of refractory Takayasu arteritis with tofacitinib evaluated by contrast-enhanced ultrasound: a case report and review of literature]","volume":"47","author":"Yang JS","year":"2022","unstructured":"Yang JS, Li M, Zhang JL, et al.. [Successful remission of refractory Takayasu arteritis with tofacitinib evaluated by contrast-enhanced ultrasound: a case report and review of literature]. Med J Chin PLA. 2022, 47:58-64. 10.11855\/j.issn.0577-7402.2022.01.0058","journal-title":"Med J Chin PLA"},{"key":"ref32","article-title":"Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases","volume":"38","author":"Palermo A","year":"2020","unstructured":"Palermo A, Marvisi C, Casali M, et al.. Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases. Clin Exp Rheumatol. 2020, 38:234-5.","journal-title":"Clin Exp Rheumatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkz050","article-title":"Refractory Takayasu arteritis responding to the oral Janus kinase inhibitor, tofacitinib","volume":"4","author":"Yamamura Y","year":"2019","unstructured":"Yamamura Y, Matsumoto Y, Asano Y, et al.. Refractory Takayasu arteritis responding to the oral Janus kinase inhibitor, tofacitinib. Rheumatol Adv Pract. 2019, 4:rkz050. 10.1093\/rap\/rkz050","journal-title":"Rheumatol Adv Pract"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2021.1911054","article-title":"Extended-release tofacitinib improves refractory Takayasu's arteritis","volume":"51","author":"Wang CR","year":"2022","unstructured":"Wang CR, Tsai YS, Liu YW, Li YH. Extended-release tofacitinib improves refractory Takayasu's arteritis. Scand J Rheumatol. 2022, 51:72-5. 10.1080\/03009742.2021.1911054","journal-title":"Scand J Rheumatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab541","article-title":"Efficacy of baricitinib for refractory large-vessel vasculitis","volume":"60","author":"R\u00e9gent A","year":"2021","unstructured":"R\u00e9gent A, Terrier B, Legendre P, Wartski M, Cohen P, Mouthon L, Le Jeunne C. Efficacy of baricitinib for refractory large-vessel vasculitis. Rheumatology (Oxford). 2021, 60:e389-91. 10.1093\/rheumatology\/keab541","journal-title":"Rheumatology (Oxford)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05741-y","article-title":"Difficult-to-treat Takayasu arteritis: a case-based review","volume":"44","author":"Belfeki N","year":"2024","unstructured":"Belfeki N, Ghriss N, Guedec-Ghelfi R, Kammoun S, Abisror N, Mekinian A. Difficult-to-treat Takayasu arteritis: a case-based review. Rheumatol Int. 2024, 44:3151-6. 10.1007\/s00296-024-05741-y","journal-title":"Rheumatol Int"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.4081\/reumatismo.2024.1796","article-title":"Baricitinib in polymyalgia rheumatica and giant cell arteritis: report of six cases","volume":"77","author":"Camellino D","year":"2025","unstructured":"Camellino D, Dejaco C, Martini F, Cosso R, Bianchi G. Baricitinib in polymyalgia rheumatica and giant cell arteritis: report of six cases. Reumatismo. 2025, 77:0. 10.4081\/reumatismo.2024.1796","journal-title":"Reumatismo"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000003913","article-title":"JAK inhibitor effectiveness in giant-cell arteritis with large-vessel involvement assessed by 18F-FDG PET-CT","volume":"47","author":"Prigent K","year":"2022","unstructured":"Prigent K, Aouba A, Aide N, de Boysson H. JAK inhibitor effectiveness in giant-cell arteritis with large-vessel involvement assessed by 18F-FDG PET-CT. Clin Nucl Med. 2022, 47:234-5. 10.1097\/RLU.0000000000003913","journal-title":"Clin Nucl Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413449","article-title":"A phase 3 trial of upadacitinib for giant-cell arteritis","volume":"392","author":"Blockmans D","year":"2025","unstructured":"Blockmans D, Penn SK, Setty AR, et al.. A phase 3 trial of upadacitinib for giant-cell arteritis. N Engl J Med. 2025, 392:2013-24. 10.1056\/NEJMoa2413449","journal-title":"N Engl J Med"},{"key":"ref40","article-title":"Successful treatment of chronic neutrophilic leukaemia and associated giant cell arteritis with the combination of ruxolitinib and azacytidine","volume":"185","author":"Herlihy N","year":"2019","unstructured":"Herlihy N, Curto-Garcia N, O\u2019Sullivan J, et al.. Successful treatment of chronic neutrophilic leukaemia and associated giant cell arteritis with the combination of ruxolitinib and azacytidine. Supplement Article: Br J Haematol. 2019, 185:3-202.","journal-title":"Supplement Article: Br J Haematol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/i9chku","article-title":"Improvements in PET\/CT results and serum cytokine profile of HLA-B52-positive patients with Takayasu's arteritis and ulcerative colitis post-tofacitinib","volume":"40","author":"Ino K","year":"2022","unstructured":"Ino K, Kinoshita N, Arinuma Y, Matsueda Y, Yamaoka K. Improvements in PET\/CT results and serum cytokine profile of HLA-B52-positive patients with Takayasu's arteritis and ulcerative colitis post-tofacitinib. Clin Exp Rheumatol. 2022, 40:849-50. 10.55563\/clinexprheumatol\/i9chku","journal-title":"Clin Exp Rheumatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216606","article-title":"Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis","volume":"79","author":"Kuwabara S","year":"2020","unstructured":"Kuwabara S, Tanimura S, Matsumoto S, Nakamura H, Horita T. Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis. Ann Rheum Dis. 2020, 79:1125-6. 10.1136\/annrheumdis-2019-216606","journal-title":"Ann Rheum Dis"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217894","article-title":"Comment on 'Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis' by Kuwabara et al","volume":"81","author":"Rios Rodriguez V","year":"2022","unstructured":"Rios Rodriguez V, Rademacher J, Protopopov M, et al.. Comment on 'Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis' by Kuwabara et al. Ann Rheum Dis. 2022, 81:e93. 10.1136\/annrheumdis-2020-217894","journal-title":"Ann Rheum Dis"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez580","article-title":"A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib","volume":"59","author":"Sato S","year":"2020","unstructured":"Sato S, Matsumoto H, Temmoku J, et al.. A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib. Rheumatology (Oxford). 2020, 59:1773-5. 10.1093\/rheumatology\/kez580","journal-title":"Rheumatology (Oxford)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac203","article-title":"Therapeutic effectiveness of upadacitinib combined with glucocorticoid on remission induction and maintenance in giant cell arteritis","volume":"61","author":"Sanada A","year":"2022","unstructured":"Sanada A, Abe N, Bohgaki M, Kasahara H. Therapeutic effectiveness of upadacitinib combined with glucocorticoid on remission induction and maintenance in giant cell arteritis. Rheumatology (Oxford). 2022, 61:e274-6. 10.1093\/rheumatology\/keac203","journal-title":"Rheumatology (Oxford)"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket128","article-title":"Development and initial validation of the Indian Takayasu clinical activity score (ITAS2010)","volume":"52","author":"Misra R","year":"2013","unstructured":"Misra R, Danda D, Rajappa SM, et al.. Development and initial validation of the Indian Takayasu clinical activity score (ITAS2010). Rheumatology (Oxford). 2013, 52:1795-801. 10.1093\/rheumatology\/ket128","journal-title":"Rheumatology (Oxford)"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham vasculitis activity score (version 3)","volume":"68","author":"Mukhtyar C","year":"2009","unstructured":"Mukhtyar C, Lee R, Brown D, et al.. Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis. 2009, 68:1827-32. 10.1136\/ard.2008.101279","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/355170-a-systematic-review-of-the-use-of-janus-kinase-inhibitors-in-large-vessel-vasculitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T14:43:42Z","timestamp":1756478622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/355170-a-systematic-review-of-the-use-of-janus-kinase-inhibitors-in-large-vessel-vasculitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":47,"URL":"https:\/\/doi.org\/10.7759\/cureus.91235","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,29]]}}}